Trial opportunity for De Novo Metastatic Prostate Cancer Study protocol summary.

Dear SAUA Members

This is a trial opportunity for de novo metastatic PCa with arms consisting of abiraterone/capivasertib (an AKT inhibitor) vs abiraterone/placebo.

We all know the benefits of trials so please make use of this opportunity.

Please email PI, Clinical Oncologist Dr Odirile Obuseng for coordination : odiobu@gmail.com

Click here for the Study summary ­ trial opportunity for de novo metastatic PCa with arms consisting of abiraterone capivasertib an AKT inhibitor vs abiraterone placebo